Is NuCana plc (NCNA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.1% / 30% | 75.1% / 30% | 51.6% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 2.1% / 33% | 75.1% / 33% | 51.6% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 1.3% / 33% | 45.7% / 33% | 31.4% / 33% | N/A | ✗ NOT HALAL |
| S&P | 2.1% / 33% | 75.1% / 33% | 51.6% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 1.3% / 33% | 45.7% / 33% | 31.4% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -193.9% | |
| Return on Assets (ROA) | -58.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$19M |
| Free Cash Flow | -$19M |
| Total Debt | $190,000 |
| Debt-to-Equity | 2.8 |
| Current Ratio | 5.6 |
| Total Assets | $15M |
Price & Trading
| Last Close | $1.48 |
| 50-Day MA | $2.25 |
| 200-Day MA | $5.50 |
| Avg Volume | 63K |
| Beta | 1.7 |
|
52-Week Range
$1.39
| |
About NuCana plc (NCNA)
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. It has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is NuCana plc (NCNA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), NuCana plc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is NuCana plc's debt ratio?
NuCana plc's debt ratio is 2.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.3%.
What are NuCana plc's key financial metrics?
NuCana plc has a market capitalization of $6M, trailing P/E ratio of inf. Return on equity stands at -193.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.